Celsion Corporation (NASDAQ:CLSN)

Shares of Celsion Corporation (NASDAQ:CLSN) fell 5.2% after the oncology drug development company reported financial results for the three and nine months ended September 30, 2017. A net loss for the two periods appears to have spooked the market, fuelling a sell-off of the stock.

CLSN Sell-Off

Following Tuesday’s sell-off, Celsion Corporation (NASDAQ:CLSN) is at risk of dropping to this year’s lows as it continues to trade in a strong downtrend. The stock has shed more than 50% in market value since the start of the year as investors continue to question the company’s long-term prospects.

However, data compiled by Zacks Investment Research indicates that two analyst firms currently rate the stock as a ‘strong buy’ amidst the growing short interest. Despite disappointing financial results, analysts are forecasting a 76.6% year over year increase in earnings. The analysts also expect earnings to grow by 48.4% next year.

For the quarter ended September 30, 2017, Celsion Corporation (NASDAQ:CLSN) reported a net loss of (-$5.7) million or (-$0.70) a share compared to a net loss of (-$6.4) million reported last year. The company attributes the decrease to a tighter clinical development focus coupled with lower operational expenses. Net loss for the first nine months came in at (-$16.1) million compared to (-$16.7) million as of last year.

Celsion Pipeline Development

During the quarter Celsion Corporation (NASDAQ:CLSN) recognized deemed dividends totaling $0.4 million with regards to multiple agreements with certain warrant holders. The company also made important milestones in the development of its lead clinical programs and capital infusion of $38 million to help drive the development efforts.

Celsion Corporation (NASDAQ:CLSN) is currently working on ThermoDox, its proprietary heat-activated liposomal encapsulation currently in Phase III for the treatment of primary liver cancer. The company’s immunotherapy program consisting of GEN-1 is currently in Phase 1 development as a localized treatment for Ovarian Cancer.

“We believe that we now have sufficient capital to complete enrollment of our Phase III OPTIMA Study and through the first efficacy analysis expected in the first quarter of 2019. Further, we expect that our current funds will allow us to make substantial progress in our open-label, randomized, 86 patient Phase I/II study of GEN-1 in newly diagnosed stage III and IV ovarian cancer patients,” said CEO, Michael Tardugno.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Asure Software Inc. (NASDAQ:ASUR)

Asure Software Inc. (NASDAQ:ASUR) shares gained 12.97% after the Austin-based maker of human capital management programs reported record revenue for the third quarter. The achievement was driven by continued growth across the entire business as the company continued to integrate multiple acquisitions made this year.

ASUR Stock Performance

The better-than-expected third quarter financial results helped strengthen the stock’s sentiments on Wall Street. Investors’ confidence appears to be slowly building up, the stock having come under pressure in recent months.

For the full year, Asure Software Inc. (NASDAQ:ASUR) is up by more than 40%. The stock faces immediate resistance at the $13.50 mark, above which it could make a push for its 52-week high of $16.03 a share.

Asure’s Q3 Financial Results

Revenue for the three months ended September 30, 2017, increased 65% to $15.5 million. Cloud revenue was up 97%, as hardware revenue increased 48% compared to the third quarter of 2016. Gross margin came in at $12.1 million or 78.1% of total revenue, representing a 64% increase from $7.4 million reported last year.

Asure Software Inc. (NASDAQ:ASUR) reported a net income per share of $0.15 a share compared to a non-GAAP net income per share of $0.22 a share reported last year. The Chief Financial Officer, Kelyn Brannon, attributes the better than expected Q3 financial results to the execution of a cloud sales initiative that helped produce solid gross margins and recurring revenue.

“Additionally, our strong cash position as well as our investments in infrastructure and processes has increased the operating leverage of our business model. Overall, our results in the third quarter reflect the increasing demand for our solutions as well as the cost and operational synergies from the strategic acquisitions we have completed this year,” said Mr. Brannon.

For the full year, Asure Software Inc. (NASDAQ:ASUR) expects revenue of between $54.25 million and $56.25 million. Excluding one-time items, Non-GAAP EBITDA should range between $12.2 million and $13.5 million. The company is also projecting Non-GAAP net loss per share of between $0.06 and $0.02 a share.

Asure Software is projecting revenues of $70 million for 2018 as it moves to integrate already completed acquisitions. The company also plans to carry out multiple ‘tuck-in” acquisitions of service bureaus, which could drive further growth.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ASUR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) fell 13.93% after the company reported on its Phase 1 clinical data for IPI-549, an oral selective phosphoinositide-3-kinase-gamma targeting immune-suppressive tumor macrophages. Trial results indicate that the candidate drug was well tolerated and clinically active.

Clinical Trial Results

The sell-off on Infinity Pharmaceuticals Inc. (NASDAQ:INFI) stock comes as a surprise, given that the biopharmaceutical company is fresh from posting a narrower than expected third-quarter net loss. However, the stock is still trading in an uptrend despite coming under pressure in recent trading sessions. The stock is up by more than 60% for the year, as it continues to outperform the overall industry.

The positive IPI-549 and Q3 financial results should affect the stock’s direction of trade heading into the end of the year.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) is evaluating IPI-549 as a monotherapy and in combination with Opdivo in patients with advanced tumors.

There is a significant need for better treatment options to take care of patients who do not respond to existing immunotherapies.

“In particular, patients with mesothelioma and adrenocortical carcinoma have limited effective treatment options, and our early evidence of activity suggests the potential for IPI-549 to improve outcomes for these patients,” said CEO Adeline Perkins.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) is to report data from a monotherapy expansion component of the study in the first half of 2018. The company also plans to report data from a combination expansion component in the first half of next year.

Infinity Q3 Financial Results

For the three months ended September 30, 2017, Infinity Pharmaceuticals posted a net loss of (-$7.1) million or (-$0.14) million, compared to a net loss of (-$19.5) million reported last year. Revenue in the quarter totaled $6 million related to amounts due from Verastem for the DUO study.

Restructuring activities in the quarter resulted in research and development expenses dropping to $9.3 million, from $12.8 million reported last year. Infinity Pharmaceuticals exited the quarter with cash and cash equivalent of $55.6 million compared to $66.2 million as of June 30, 2016. General and Administrative expenses also dropped because of the restructuring activities to $4.5 million from $7.1 million a year ago.

For the full year, the biopharmaceutical company is projecting a net loss of between $40 million and $50 million. Cash and cash equivalents should range from $40 million and $50 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $INFI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Management remarks

The stock is currently trading at a key support level of $2.65, below which it could drop to the next support level at $2.20. BioDelivery Sciences has come under pressure in recent weeks after touching highs of $3.40 a share. Observers are keen to see if the third quarter financial results is the catalyst that will help push the stock up.

According to the Chief Executive Officer, Mark Sirgo, the solid performance in the quarter was because of the strong sales momentum behind lead product BELBUCA.

“Our solid performance in the third quarter continued the encouraging trend we have seen with BELBUCA, as we achieved prescription growth of 15% over the second quarter. The favorable trend continued into October as BELBUCA monthly total prescriptions reached an all-time high in excess of 8,000 based on preliminary sales data,” said Mr. BELBUCA.

The executive expects continued growth of BELBUCA going forward due to a new sales strategy and improved managed care involving Medicare. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has also completed an important licensing agreement with Purdue Pharma for BELBUCA.

Q3 Financial Results

Net Revenue for the three months ended September 30, 2017, came in at $11.3 million, up from $3.6 million reported in the third quarter of 2016. BELBUCA and BUNAVAIL revenue totaled $6.4 million and $1.7 million respectively. Net revenue for the first nine months of the year totaled $49.5 million compared to $11.6 million in the same period last year.

Total operating expenses for the quarter was $16.9 million compared to $16.5 million reported last year. Net loss decreased to (-$12 million) or (-$0.21) a share compared to a net loss of (-$16) million or (-$0.30) a share, reported last year. The decrease in net loss was primarily attributed to net profitability from the reacquisition of BELBUCA early in the year.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has cash and cash equivalents of $19.7 million compared to $27.5 million as of June 30, 2017. During the quarter, the company met the financial requirements needed to access the next $15 million tranche in its loan agreement with CRG.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BDSI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Cartesian Inc (NASDAQ:CRTN)

Cartesian Inc (NASDAQ:CRTN) stock nearly doubled on Friday even though there was no news released by the company or reported by any of the major news services. CRTN shares closed at $0.26 on Thursday then gapped up to open on Friday at $0.29, hit an inter-day high about one hour into trading at $1.00, and closed the session at $0.51.

The company will be announcing their Q3 2017 financial results after the market closes on Monday, November 13, 2017. A conference call to explain the results will follow.

CRTN Delists

On November 2, 2017, Cartesian Inc (NASDAQ:CRTN) notified the Nasdaq Stock Market that it would voluntarily delist its common stock at the close of business on November 13, 2017. Cartesian is currently taking the steps necessary to have its common stock begin trading in the OTCQB Market, operated by OTC Markets Group.

Cartesian’s Board of Directors approved the voluntary withdrawal of the Company’s common stock from listing on the NCM as a result of numerous factors, including its assessment of the probability of the Company’s regaining compliance with the Rule and complying with certain other Nasdaq quantitative requirement.

CRTN Stock Performance

Q2 2017 revenues decreased by 31% to $13.0 million from $18.9 million for the same period in 2016. Q2 2017 net loss was (-$1.4) million, or (-$0.16) per diluted share, compared to a net loss of (-$12.9) million, or (-$1.49) per diluted share in Q2 2016.

Follow the company’s Q2 earnings release, CRTN stock traded, mostly in a range between $0.50 and $0.70 through the end of October. Then at the beginning of November, CRTN shares dived below $0.30 until the massive upward move last Friday. Year-to-date, CRTN stock is down 44%.

Sales increased from 2012 when the company reported sales of $53 million, until 215 when the company posted sales of $78.3 million. Then, in 2016, sales decreased to a figure of $71.7 million.

Earnings have been worse. They have not produced positive earnings in the past five years. The per share loss expanded from 2014 (-$0.18) to a figure of (-$1.81) in 2016.

No investment analysts follow the firm – likely due to the fact that its market capitalization is below $5 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CRTN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

OHR Pharmaceutical Inc (NASDAQ:OHRP)

Shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) closed higher by over 12% today on a volume figure that was over five times the listed average. Despite a lack of news concerning the pharmaceutical company, traders bid the company’s shares higher throughout the day but sellers stepped in with two hours left in the trading day and started to pressure the stock whenever it got over $0.70. OHRP shares ended the day at $0.69.

OHR Pharmaceutical, Inc. (NasdaqCM:OHRP) develops therapeutics and delivery technologies for the treatment of ocular diseases. Their pre-clinical pipeline is focused on the development of sustained release therapeutics for ocular diseases utilizing their patented microfabrication platform technology. OHR Pharmaceutical Inc (NASDAQ:OHRP) currently has several active programs evaluating molecules and approaches for the treatment of primary open angle glaucoma, steroid-induced glaucoma, ocular allergies, and retinal diseases. The U.S. Food and Drug Administration has awarded OHR’s Squalamine Fast Track Designation for the potential treatment of wet AMD.

OHRP Stock History

OHR Pharmaceutical Inc (NASDAQ:OHRP) shares hit their peak in 2014 when OHRP was trading, albeit briefly, just below $20 per share. However, shares are now struggling to stay above the $1 threshold which not only is psychologically important, but also triggers a NASDAQ compliance rule.

In 2012 the company reported a per share loss of (-$0.10). That loss expanded each year and in 2016 the per share loss was reported at (-$0.82). A lack of earnings is not unusual for a biotechnology firm that typically has a multi-year runway to revenues due to FDA approval requirements. But the company was also diluting shareholder equity during this time. In 2012 the number of outstanding shares stood at 14.24 million. That figure expanded every year and for 2016 the company listed the number of outstanding shares at 31.35 million.

Accordingly, shares have lost nearly 60% of their value year-to-date, and nearly 80% for the year. While shares are well above their 52-week low of $0.56, they are far away from their 52-week high of $3.10, and even further away from analysts’ consensus, one-year price target of $10.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OHRP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Cerus Corporation (NASDAQ:CERS)

Cerus Corporation (NASDAQ:CERS) stock has broken through a resistance trend line and is up a whopping 20.5% after the company reported losses that beat street expectations. reported a loss of $13.4 million in its third quarter. Concord, CA-based Cerus Corporation reported a (-$0.12) per share loss against the (-$0.15) loss analysts were expecting.

Cerus Corporation (NASDAQ:CERS) is a biomedical company that develops products to improve the safety profile of blood transfusions. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections. Cerus currently markets and sells the INTERCEPT Blood System globally.

Cerus Q3 Earnings

Operating losses from Q3 2017 were $12.4 million, compared to $14.3 million for the same period in 2016, and $46.7 million compared to $46.3 million for the nine months ended September 30, 2017 and September 30, 2016, respectively.

Net loss for Q3 2017 was $13.4 million, or (-$0.12) per diluted share, compared to a net loss of (-$14.4) million, or (-$0.14) per diluted share, for the third quarter of 2016. Net loss for the first nine months of 2017 was (-$49.1) million, or (-$0.46) per diluted share, compared to a net loss of (-$49.4) million, or (-$0.49) per diluted share, for the same period of 2016.

CERS Stock

In mid-2016, CERS shares were briefly trading over $7.00, but then started a slow, steady slide until they hit their 52-week low of $1.93 in May of 2017. Accordingly, the stock has lost about 33% year-to-date. However shares have gained over 16% during the past quarter. The recent gains have been reflected in the company’s Relative Strength Index score of 73 – a number above 70 is usually taken to signal an “overbought” condition.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CERS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Marathon Patent Group Inc. (NASDAQ:MARA)

Marathon Patent Group Inc. (NASDAQ:MARA) fell 19% after announcing a definitive agreement to acquire 100% ownership of Global Bit Ventures. The acquisition will expand the company’s operations into the cryptocurrency business.

Global Bit Venture Acquisition

Global Bit Ventures has developed a robust infrastructure that Marathon Patent Group Inc. (NASDAQ:MARA) plans to take advantage of, in its pursuit of growth opportunities around digital currencies. According to Chief Executive Officer, Doug Croxall, the acquisition underscores the company’s commitment to enhancing shareholders value by pursuing alternative business directions.

Prior to the acquisition of Global Bit Ventures, Marathon Patent Group Inc. (NASDAQ:MARA) was focused on the business of acquiring patents and patent rights from owners and other ventures. The company generates a good chunk of its earnings from monetization of the patent portfolio through license discussions. However, with the acquisition of GBV, its revenue stream should receive a boost.

“We believe the acquisition of Global Bit Ventures will take advantage of an ongoing revolution in digital transactions conducted on blockchain as we see increasing adoption and proliferation of blockchain protocols in our everyday lives,” said Mr. Croxall.

GBV boasts of a technology that powers and secures blockchain by operating custom hardware and software. GBV currently owns 250GH/s of GPU mining servers and plans to add 14PH/s of ASIC servers to further strengthen its prospects in the merging industry. The company’s director, Charles Allen, expects the merger to position the company for rapid revenue growth in the years to come.

Marathon Patent Group Inc. (NASDAQ:MARA) has been trading in a downtrend for the better part of the year. Investor’s sentiments has hit all-time lows at the back of a strong sell-off wave. The stock is down by more than 70% for the year as it continues to trade near its 52-week low of $1.49 a share.

Reverse Stock Split

Separately, Marathon Patent Group Inc. (NASDAQ:MARA) has initiated a four-for-one reverse-split for its outstanding common stock. The reverse split will reduce the company’s common stock from about 32.4 million shares to 8.6 million shares. The company is hoping the split will shore up the stock price thereby bring the company into compliance with the NASDAQ Capital Market minimum average closing price of $1 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MARA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Ocera Therapeutics Inc (NASDAQ:OCRX)

Ocera Therapeutics Inc (NASDAQ:OCRX) shares rocketed over 65% higher today after the company announced it is being acquired by UK-based Mallinckrodt plc for $1.52 per share. The news sent investors scrambling to buy shares in the new company and share volume is on pace to register a figure over 120 times the normal daily average.

Why Ocera Therapeutics is Attractive

Ocera Therapeutics Inc (NASDAQ:OCRX) is a clinical stage biopharmaceutical company that developing OCR-002 (ornithine phenylacetate) in both intravenous (IV) and oral formulations. OCR-002 is an ammonia scavenger and has been granted Orphan Drug designation (ODD) and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure and acute-on-chronic liver disease.

Although the STOP-HE study7 did not meet its primary endpoint, it achieved secondary endpoints that validated OCR-002 as a potent ammonia scavenger. In a subsequent analysis of the data, it was observed that the degree of ammonia reduction in patients correlated strongly with clinical improvement. As the response rate also appeared to increase proportionally to dose level, this suggests that some patients in the Phase 2 trial may have been under-dosed. The IV formulation of OCR-002, if approved, is expected to provide rapid reduction in symptoms of acute HE, and potentially reduce hospitalization stay. A subset of patients continues to have HE symptoms after discharge. OCR-002’s oral formulation, if approved, is expected to provide post-discharge continuity of care for the HE patient, reducing the risk of recurrent HE episodes and rehospitalization.

The Purchaser

Mallinckrodt plc, headquartered in Staines-upon-Thames, England is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. Mallinckrodt’s core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities.

A subsidiary of Mallinckrodt plc will commence a cash tender offer to purchase all of Ocera Therapeutics Inc (NASDAQ:OCRX) outstanding shares for $1.52 per share (approximately $42 million), plus one Contingent Value Right to receive one or more payments in cash of up to $2.58 per share (up to approximately $75 million) based on the successful completion of certain development and sales milestones. Mallinckrodt plc expects dilution from the acquisition to adjusted diluted earnings per share by $0.25 to $0.35 annually beginning in 2018.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OCRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Eleven Biotherapeutics Inc. (NASDAQ:EBIO)

Eleven Biotherapeutics Inc. (NASDAQ:EBIO) fell 22.11% after announcing the pricing of an underwritten public offering of 5.5 million shares of common stock. The late-stage clinical oncology company is also offering pre-funded warrants for the purchase of an aggregate 4.5 million shares of common stock as well as common warrants for the purchase of up to 10 million shares.

Public Offering

The company is offering each share of common stock or pre-funded warrant at a combined effective price of $0.80 a share. Eleven Biotherapeutics Inc. (NASDAQ:EBIO) has also granted underwriters a 30-day option to purchase an addition 1.5 million shares of common stock at a price of $0.79 a share

H.C Wainwright & Co., LLC is acting as the book-running manager for the offering. The offering should close on or about November 3, 2017, subject to customary closing conditions

Eleven Biotherapeutics Inc. (NASDAQ:EBIO) expects gross proceeds of approximately $8 million prior to the deduction of underwriting discounts and commissions among other offering expenses. The company plans to use the net proceeds to finance clinical development of its lead product candidate Vicinium.

The late-stage clinical oncology company has already completed manufacturing of all the Vicinium necessary for its Phase 3 registration trial. The trial seeks to evaluate the candidate drug’s ability to treat non-muscle invasive bladder cancer

Eleven Biotherapeutics Inc. (NASDAQ:EBIO) continues to trade lower for the better part of the year. Investors’ confidence in the stock has taken a hit amidst stock dilution concerns and the fact that the company could be sinking further into debt. The stock has shed more than 60% in market value since the start of the year.

CFO Appointment

Separately, Eleven Biotherapeutics Inc. (NASDAQ:EBIO) has confirmed the appointment of Richard F. Fitzgerald as the Interim Chief Financial Officer. He replaces John McCabe who stepped down from the post. Fitzgerald joins the company with over two decades of financial and strategic leadership.

“We are pleased to welcome Richard to the management team at eleven. He brings significant experience in capital raising and strategic leadership to the company, as we look forward to top-line three-month data from our Phase 3 trial of our lead drug candidate Vicinium in mid-2018,” said Stephen Hurly, Chief Executive Officer of Eleven Biotherapeutics Inc. (NASDAQ:EBIO).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EBIO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Posts navigation

StockNewsUnion is a news gathering organization led by a team of unbiased, investment professionals dedicated to following the market’s biggest headline stocks on a daily basis. Our goal is to provide unmatched news and insight on newsworthy and momentum stocks to investors and traders worldwide.

Special attention is given to Nasdaq and listed US stocks trading under ten dollars that tend to have the largest street following.

We focus on identifying these companies and uncovering their stories before the rest of the market to ensure that you receive the full story – every single day.